Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds. J Biomol Screen 2008 Sep;13(8):795-803
Date
07/31/2008Pubmed ID
18664715Pubmed Central ID
PMC2693415DOI
10.1177/1087057108321085Scopus ID
2-s2.0-51249095826 (requires institutional sign-in at Scopus site) 10 CitationsAbstract
Astrocytoma/glioblastoma is the most common malignant form of brain cancer and is often unresponsive to current pharmacological therapies and surgical interventions. Despite several potential therapeutic agents against astrocytoma and glioblastoma, there are currently no effective therapies for astrocytoma, creating a great need for the identification of effective antitumor agents. The authors have developed a novel dual-reporter system in Trp53/Nf1-null astrocytoma cells to simultaneously and rapidly assay cell viability and cell cycle progression as evidenced by activity of the human E2F1 promoter in vitro. The dual-reporter high-throughput assay was used to screen experimental therapeutics for activity in Trp53/Nf1-null astrocytoma. Several compounds were identified demonstrating selectivity for astrocytoma over primary astrocytes. The dual-reporter system described here may be a valuable tool for identifying potential antitumor treatments that specifically target astrocytoma.
Author List
Hawes JJ, Nerva JD, Reilly KMAuthor
John D. Nerva MD Assistant Professor in the Neurosurgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsAntineoplastic Agents
Astrocytoma
Camptothecin
Cytostatic Agents
Cytotoxins
Drug Evaluation, Preclinical
Genes, Reporter
Humans
Nocodazole
Reproducibility of Results